KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Capital Expenditures (2016 - 2025)

Sarepta Therapeutics has reported Capital Expenditures over the past 15 years, most recently at $3.6 million for Q4 2025.

  • Quarterly results put Capital Expenditures at $3.6 million for Q4 2025, down 90.57% from a year ago — trailing twelve months through Dec 2025 was $102.0 million (down 25.54% YoY), and the annual figure for FY2025 was $102.0 million, down 25.54%.
  • Capital Expenditures for Q4 2025 was $3.6 million at Sarepta Therapeutics, down from $22.9 million in the prior quarter.
  • Over the last five years, Capital Expenditures for SRPT hit a ceiling of $43.7 million in Q1 2025 and a floor of $2.2 million in Q4 2021.
  • Median Capital Expenditures over the past 5 years was $18.5 million (2023), compared with a mean of $19.2 million.
  • Biggest five-year swings in Capital Expenditures: tumbled 92.29% in 2021 and later surged 261.02% in 2022.
  • Sarepta Therapeutics' Capital Expenditures stood at $2.2 million in 2021, then surged by 261.02% to $8.0 million in 2022, then surged by 139.06% to $19.0 million in 2023, then surged by 100.02% to $38.1 million in 2024, then plummeted by 90.57% to $3.6 million in 2025.
  • The last three reported values for Capital Expenditures were $3.6 million (Q4 2025), $22.9 million (Q3 2025), and $31.8 million (Q2 2025) per Business Quant data.